Nexentis Technologies Inc. (NXTS)
NASDAQ: NXTS · Real-Time Price · USD
1.390
+0.010 (0.72%)
At close: Oct 6, 2026, 4:00 PM EDT
1.320
-0.070 (-5.04%)
Pre-market: Oct 7, 2026, 4:33 AM EDT
Nexentis Technologies Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
9
Market Cap
2.02M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 263.00K | -131.00K | -33.25% |
| Dec 31, 2022 | 394.00K | -44.14K | -10.07% |
| Dec 31, 2021 | 438.14K | 205.87K | 88.63% |
| Dec 31, 2020 | 232.27K | 56.45K | 32.11% |
| Dec 31, 2019 | 175.82K | -250.77K | -58.78% |
| Dec 31, 2018 | 426.59K | 82.66K | 24.04% |
| Dec 31, 2017 | 343.93K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Corteva | 17.81B |
| The Mosaic Company | 12.25B |
| CF Industries Holdings | 7.74B |
| ICL Group | 7.71B |
| The Scotts Miracle-Gro Company | 3.48B |
| FMC Corporation | 3.25B |
| CVR Partners | 676.86M |
| American Vanguard | 510.32M |
NXTS News
- 12 days ago - Nexentis Technologies appoints Major to Scientific Advisory Board - TheFly
- 12 days ago - Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board - GlobeNewsWire
- 13 days ago - Nexentis subsidiary evaluates ways for obtaining proteins in in-vitro research - TheFly
- 13 days ago - Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery - GlobeNewsWire
- 2 months ago - Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign - GlobeNewsWire
- 2 months ago - Nexentis Technologies registers to sell 2.57M shares of common stock for holders - TheFly
- 3 months ago - Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative - GlobeNewsWire
- 3 months ago - Nexentis Technologies announces monetization of Melz solar investment - TheFly